Expert Ratings for Syneos Health
Analysts have provided the following ratings for Syneos Health (NASDAQ:SYNH) within the last quarter:
Citigroup Maintains Neutral on Syneos Health, Lowers Price Target to $55
Citigroup analyst Patrick Donnelly maintains Syneos Health (NASDAQ:SYNH) with a Neutral and lowers the price target from $70 to $55.
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 574 stocks hit new 52-week lows.
Baird Maintains Outperform on Syneos Health, Lowers Price Target to $80
Baird analyst Eric Coldwell maintains Syneos Health (NASDAQ:SYNH) with a Outperform and lowers the price target from $89 to $80.
Benzinga’s Top Ratings Upgrades, Downgrades For September 14, 2022
Upgrades
For Iris Energy Ltd (NASDAQ:IREN), Compass Point upgraded the previous rating of Neutral to Buy. The current stock performance of Iris Energy shows a 52-week-high of $17.97 and a 52-week-low of $2.89. Moreover, at the end of the last trading period, the closing price was at $4.26.
Tesla, Meta, NVIDIA And Other Big Losers From Tuesday
U.S. stocks closed sharply lower with the Nasdaq Composite dipping more than 5% on Tuesday. Here is the list of some big stocks moving lower in the previous session.
Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
Gainers
Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX dose groups.
Analyst Ratings for Syneos Health
Within the last quarter, Syneos Health (NASDAQ:SYNH) has observed the following analyst ratings: